Risk of Guillain-Barré syndrome following herpes zoster, United States, 2010–2018

References

• Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gener Intern Med. 2005;20:748–53. doi:10.1111/j.1525-1497.2005.0150.x.
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR–5):1–30.
   PubMedGoogle Scholar
• Harpaz R, Leung JW. The epidemiology of herpes zoster in the United States during the era of varicella and herpes zoster vaccines: changing patterns among older adults. Clin Infect Dis. 2019;69(2):341–44. doi:10.1093/cid/ciy953.
   PubMed Web of Science ®Google Scholar
• Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92:1806–21. doi:10.1016/j.mayocp.2017.10.009.
   PubMed Web of Science ®Google Scholar
• McKay SL, Guo A, Pergam SA, Dooling K. Herpes zoster risk in immunocompromised adults in the United States: a systematic review. Clin Infect Dis. 2020;71(7):e125–34. doi:10.1093/cid/ciz1090.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011;60:1528.
   PubMedGoogle Scholar
• Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729–31.
   PubMed Web of Science ®Google Scholar
• Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103–08. doi:10.15585/mmwr.mm6703a5.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Shingrix US package insert, Revised: 07/2021. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https://www.fda.gov/media/108597/download .
   Google Scholar
• Anderson TC. Work Group interpretation of the Evidence to Recommendations Framework regarding use of RZV in immunocompromised adults, considerations for use, and proposed policy options. October 2021 Advisory Committee on Immunization Practices (ACIP) Meeting. 2021. https://www.cdc.gov/vaccines/acip/meetings/slides-2021-10-20-21.html .
   Google Scholar
• Centers for Disease Control & Prevention. What everyone should know about Zostavax. 2020 [accessed 2020 Dec 24]. https://www.cdc.gov/vaccines/vpd/shingles/public/zostavax/ .
   Google Scholar
• Hesse EM, Shimabukuro TT, Su JR, Hibbs BF, Dooling KL, Goud R, Lewis P, Ng CS, Cano MV. Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix) — United States, October 2017–June 2018. MMWR Morb Mortal Wkly Rep. 2019;68(4):91–94. doi:10.15585/mmwr.mm6804a4 .
   Google Scholar
• Su JR. Update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix). October 2020 Advisory Committee on Immunization Practices (ACIP) Meeting. 2020. https://www.cdc.gov/vaccines/acip/meetings/slides-2020-10.html .
   Google Scholar
• Nelson JC. Vaccine Safety Datalink (VSD) update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix). October 2020 Advisory Committee on Immunization Practices (ACIP) Meeting. 2020. https://www.cdc.gov/vaccines/acip/meetings/slides-2020-10.html .
   Google Scholar
• Shimabukuro T. Update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix). June 2019 Advisory Committee on Immunization Practices (ACIP) Meeting. 2019. https://www.cdc.gov/vaccines/acip/meetings/slides-2020-10.html .
   Google Scholar
• Goud R, Lufkin B, Duffy J, Whitaker B, Wong H-L, Liao J, Lo A-C, Parulekar S, Agger P, Anderson SA, et. al. Risk of Guillain-Barré Syndrome following Recombinant Zoster Vaccine in Medicare. JAMA Internal Medicine. November 2021. doi:10.1001/jamainternmed.2021.6227 .
   Google Scholar
• Yadav R, Hundley D, Cation L. Severe Guillain-Barré syndrome following Shingrix vaccine administration. J Neurol Neurosci. 2019;10(4):301. doi:10.36648/2171-6625.10.4.301.
   Google Scholar
• Tripathi A, Dharapak P, Laskova V. A case of Guillain-Barré syndrome (GBS) following zoster vaccination. J Gener Intern Med. 2020;35:S341–42.
   PubMed Web of Science ®Google Scholar
• Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366:1653–66. doi:10.1016/S0140-6736(05)67665-9.
   PubMed Web of Science ®Google Scholar
• Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123–33. doi:10.1159/000324710.
   PubMed Web of Science ®Google Scholar
• Beghi E, Kurland LT, Mulder DW, Wiederholt WC, Guillain-Barre syndrome. Clinicoepidemiologic features and effect of influenza vaccine. Arch Neurol. 1985;42:1053–57. doi:10.1001/archneur.1985.04060100035016.
   PubMedGoogle Scholar
• Kaplan JE, Schonberger LB, Hurwitz ES, Katona P. Guillain-Barré syndrome in the United States, 1978–1981: additional observations from the national surveillance system. Neurology. 1983;33:633–37. doi:10.1212/WNL.33.5.633.
   PubMed Web of Science ®Google Scholar
• Shui IM, Rett MD, Weintraub E, Marcy M, Amato AA, Sheikh SI, Ho D, Lee GM, Yih WK, Vaccine Safety Datalink Research Team. Guillain-Barré syndrome incidence in a large United States cohort (2000–2009). Neuroepidemiology. 2012;39:109–15. doi:10.1159/000339248.
   PubMed Web of Science ®Google Scholar
• Leung J, Sejvar JJ, Soares J, Lanzieri TM. Guillain-Barré syndrome and antecedent cytomegalovirus infection, USA 2009–2015. Neurol Sci. 2020;41(4):885–91. doi:10.1007/s10072-019-04156-z.
   PubMed Web of Science ®Google Scholar
• Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Saf. 2009;32(4):309–23. doi:10.2165/00002018-200932040-00005.
   PubMed Web of Science ®Google Scholar
• McGrogan A, Madle GC, Seaman HE, De Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32:150–63. doi:10.1159/000184748.
   PubMed Web of Science ®Google Scholar
• Willison HJ, Jacobs BC, Van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388:717–27. doi:10.1016/S0140-6736(16)00339-1.
   PubMed Web of Science ®Google Scholar
• Counotte MJ, Egli-Gany D, Riesen M, Abraha M, Porgo TV, Wang J, Low N. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: from systematic review to living systematic review. F1000Research. 2018;7:196.
   PubMedGoogle Scholar
• Hart IK, Kennedy PGE. Guillain-Barré syndrome associated with herpes zoster. Postgrad Med J. 1987;63:1087–88. doi:10.1136/pgmj.63.746.1087.
   PubMed Web of Science ®Google Scholar
• Sanders EACM, Peters ACB, Gratana JW, Hughes RAC. Guillain-Barré syndrome after varicella-zoster infection. J Neurol. 1987;234:437–39. doi:10.1007/BF00314094.
   PubMed Web of Science ®Google Scholar
• Rabbani MU, Gupta D. Guillain Barré syndrome following herpes zoster: a case report and review of literature. Jpn J Med. 1990;29(4):397–98. doi:10.2169/internalmedicine1962.29.397.
   PubMedGoogle Scholar
• Roccatagliata L, Uccelli A, Murialdo A. Guillain–Barré syndrome after reactivation of varicella–zoster virus. N Engl J Med. 2001;344:65–66.
   PubMed Web of Science ®Google Scholar
• Kang J-H, Sheu -J-J, Lin H-C. Increased risk of Guillain-Barré syndrome following recent herpes zoster: a population-based study across Taiwan. Clin Infect Dis. 2010;51(5):525–30. doi:10.1086/655136.
   PubMed Web of Science ®Google Scholar
• Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51:228–35. doi:10.2307/2533328.
   PubMed Web of Science ®Google Scholar
• Weldeselassie YG, Whitaker HJ, Farrington CP. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiol Infect. 2011;139:1805–17. doi:10.1017/S0950268811001531.
   PubMed Web of Science ®Google Scholar
• Hua W, Sun G, Dodd CN, Romio SA, Whitaker HJ, Izurieta HS, Black S, Sturkenboom MCJM, Davis RL, Deceuninck G, et al. A simulation study to compare three self-controlled case series approaches: correction for violation of assumption and evaluation of bias. Pharmacoepidemiol Drug Saf. 2013;22:819–25. doi:10.1002/pds.3451.
   PubMed Web of Science ®Google Scholar
• Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354:i4515. doi:10.1136/bmj.i4515.
   PubMed Web of Science ®Google Scholar
• Baker MA, Lieu TA, Li L, Hua W, Qiang Y, Kawai AT, Fireman BH, Martin DB, Nguyen MD. A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program. Am J Epidemiol. 2015;181:608–18. doi:10.1093/aje/kwu322.
   PubMed Web of Science ®Google Scholar
• Li R, Stewart B, Weintraub E. Evaluating efficiency and statistical power of self-controlled case series and self-controlled risk interval designs in vaccine safety. J Biopharm Stat. 2016;26:686–93. doi:10.1080/10543406.2015.1052819.
   PubMed Web of Science ®Google Scholar
• Webb AJS, Brain SAE, Wood R, Rinaldi S, Turner MR. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry. 2015;86:1196–201. doi:10.1136/jnnp-2014-309056.
   PubMed Web of Science ®Google Scholar